Kodiak Sciences Inc (KOD)
Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing therapies for retinal diseases. The company’s lead candidate is tarcocimab tedromer (KSI-301), an anti-VEGF antibody biopolymer being studied in late-stage clinical programs for conditions including diabetic retinopathy, wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema, as well as in a Phase 2/3 study for wet AMD. Its preclinical pipeline also includes KSI-501, a bispecific antibody biopolymer conjugate targeting IL-6 and VEGF for retinal vascular diseases, and KSI-101 (KSI-501P), a bispecific protein designed for patients with retinal fluid and inflammation. Founded in 2009 and formerly known as Oligasis, LLC, the company is based in Palo Alto, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KOD
|
$29.30
|
-31.7% Downside
|
Overvalued
|
$62.67
|
46.1% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-11.6x
|
23.8x
|
—
|
2.552 B
|
2.553 B
|
2.1%
|
62.9%
|
-1.6
|
—
|
64.2%
|
